The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care
Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.
-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI
-
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
National Cyber Strategy Enables FBI to Disrupt Cybercriminals
The White House plan helped amplify and clarify the Bureau's role in law enforcement efforts, FBI Cyber DAD Cynthia Kaiser says.
13m listen -
How FBI Takes Down Cybercrime Superstores
Operation Cookie Monster was a success because of partnerships, FBI officials say.
13m listen -
VA Watchtower Monitors Critical Apps to Thwart Disruptions
The tool provides a real-time view on agency systems to address glitches and system issues before they affect services.
17m listen -
NCI Program Unlocks Emerging Proteomic Data to Advance Precision Medicine
Researchers say sharing molecular cancer research data can expand cancer treatment and care.
32m listen